NanoVibronix Inc (Nasdaq: NAOV), a medical device company headquartered in Elmsford, New York, on Tuesday announced the signing of a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial (RCT) study of UroShield.
This clinical study aims to gather additional evidence supporting NanoVibronix's application to the FDA for permanent clearance of the UroShield device.
The company' proprietary technology, which utilises patented low-intensity surface acoustic wave (SAW) technology, allows for the creation of low-frequency ultrasound waves that can be used for medical applications such as disruption of biofilms and bacterial colonisation, as well as for pain relief.
NanoVibronix's primary products, PainShield and UroShield, are portable devices designed for home use without the need for medical professional assistance.
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
Syndax Pharmaceuticals grants share purchase inducement awards to six new employees
Hippo Pharmacy launches fast, free delivery on orders over USD150
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review